Literature DB >> 15634862

Efficacy of boric-complexed zinc and acetic-complexed zinc otic preparations for canine yeast otitis externa.

Colleen L Mendelsohn1, Craig E Griffin, Wayne S Rosenkrantz, Larry D Brown, Mona J Boord.   

Abstract

The purpose of this 2-week, double-blinded, controlled clinical trial was to evaluate the efficacy of topical amino acid-complexed zinc gluconate formulated with boric acid (ZGB) or acetic acid (ZGA) versus a topical placebo in the treatment of yeast otitis externa in dogs. Included in the study were dogs with otitis externa and a cytopathological finding of yeast organisms in the affected ear. Ears were treated with the placebo, ZGA, or ZGB medications. Yeast counts as well as clinical appearance of the ears were monitored. Results revealed that ZGB significantly reduced the number of yeast organisms in cases of otitis externa.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15634862     DOI: 10.5326/0410012

Source DB:  PubMed          Journal:  J Am Anim Hosp Assoc        ISSN: 0587-2871            Impact factor:   1.023


  3 in total

1.  Comparison of Boric Acid and Combination Drug of Polymyxin, Neomycin and Hydrocortisone (polymyxin NH) in the Treatment of Acute Otitis Externa.

Authors:  Soroush Amani; Mohammad Moeini
Journal:  J Clin Diagn Res       Date:  2016-07-01

2.  Clinical evaluation of an antiinflammatory and antioxidant diet effect in 30 dogs affected by chronic otitis externa: preliminary results.

Authors:  Alessandro Di Cerbo; Sara Centenaro; Francesca Beribè; Fulvio Laus; Matteo Cerquetella; Andrea Spaterna; Gianandrea Guidetti; Sergio Canello; Giuseppe Terrazzano
Journal:  Vet Res Commun       Date:  2016-01-07       Impact factor: 2.459

3.  A randomized, controlled, single-blinded, multicenter evaluation of the efficacy and safety of a once weekly two dose otic gel containing florfenicol, terbinafine and betamethasone administered for the treatment of canine otitis externa.

Authors:  S B King; K P Doucette; W Seewald; S L Forster
Journal:  BMC Vet Res       Date:  2018-10-11       Impact factor: 2.741

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.